Fourth quarter (October-
** Other operating income amounted to KSEK 256 (3,335)
** Operating loss was KSEK -11,759 (-13,552)
** Loss for the quarter totaled KSEK -11,465 (-13,529)
** Cash flow from operating activities was KSEK -12,591 (-15,074)
** Loss per share before dilution was
** The proposed dividend is
Period (January-
** Other operating income amounted to KSEK 414 (13,915)
** Operating loss was KSEK -47,972 (-38,965)
** Loss for the quarter totaled KSEK -47,750 (-38,854)
** Cash flow from operating activities was KSEK -50,703 (-40,190)
** Loss per share before dilution was
Significant events in the fourth quarter
** First patient is included in
Idogen 'sIdogen sharpens focus on its IDO 8 program, pauses the IDO T and IDO programs and lowers operating expenditure.
**
** First patient enters
** EU to disburse the remaining of the Horizon 2020 grant.
**
** The board of
**
Significant events in the period
**
** Idogens presented the company's tolerogenic cell therapy platform at the 5th Antigen-Specific Immune
Tolerance Summit.
**
**
**
for IDO 8.
**
**
**
**
**
** An extraordinary general meeting of shareholders on
chairman and
**
Significant events after the end of the period
** New issue gives proceed of net 5.3 MSEK after costs.
**
**
** No other significant events occurred after the end of the period that affected the results or financial position.
For further information, please contact:
Tel: +46 70 374 71 56
E-mail: christina.herder@idogen.com
Certified Adviser:
The information was submitted for publication, through the agency of the contact persons set out above, on
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
https://news.cision.com/idogen/r/idogen-publishes-interim-report-for-1-january---31-december-2022,c3723091
https://mb.cision.com/Main/12368/3723091/1874717.pdf
https://mb.cision.com/Public/12368/3723091/baa1e69159b08898.pdf
(c) 2023 Cision. All rights reserved., source